These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25978147)

  • 1. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature.
    Bielopolski D; Evron E; Moreh-Rahav O; Landes M; Stemmer SM; Salamon F
    J Chemother; 2017 Apr; 29(2):113-117. PubMed ID: 25978147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
    Yu TK; Whitman GJ; Thames HD; Buzdar AU; Strom EA; Perkins GH; Schechter NR; McNeese MD; Kau SW; Thomas ES; Hortobagyi GN; Buchholz TA
    J Natl Cancer Inst; 2004 Nov; 96(22):1676-81. PubMed ID: 15547180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel-induced acute bilateral pneumonitis.
    Khan A; McNally D; Tutschka PJ; Bilgrami S
    Ann Pharmacother; 1997 Dec; 31(12):1471-4. PubMed ID: 9416383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of paclitaxel-induced pneumonitis].
    Taniguchi N; Shinagawa N; Kinoshita I; Nasuhara Y; Yamazaki K; Yamaguchi E; Akita H; Nishimura M
    Nihon Kokyuki Gakkai Zasshi; 2004 Feb; 42(2):158-63. PubMed ID: 15007916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
    Burstein HJ; Bellon JR; Galper S; Lu HM; Kuter I; Taghian AG; Wong J; Gelman R; Bunnell CA; Parker LM; Garber JE; Winer EP; Harris JR; Powell SN
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):496-504. PubMed ID: 16243442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
    Hudis C; Seidman A; Raptis G; Fennelly D; Gilewski T; Baselga J; Theodoulou M; Sklarin N; Moynahan M; Surbone A; Currie V; Lebwohl D; Uhlenhopp M; Crown J; Norton L
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):58-64. PubMed ID: 8629040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
    Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
    Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
    Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.
    Ostoros G; Pretz A; Fillinger J; Soltesz I; Dome B
    Int J Gynecol Cancer; 2006; 16 Suppl 1():391-3. PubMed ID: 16515630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe interstitial pneumonitis associated with the administration of taxanes.
    Nagata S; Ueda N; Yoshida Y; Matsuda H; Maehara Y
    J Infect Chemother; 2010 Oct; 16(5):340-4. PubMed ID: 20354889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.
    Tolcher AW
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):37-43. PubMed ID: 8629035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe interstitial pneumonia induced by paclitaxel in a patient with adenocarcinoma of the lung.
    Suzaki N; Hiraki A; Takigawa N; Ueoka H; Tanimoto Y; Kozuki T; Tabata M; Kanehiro A; Kiura K; Tanimoto M
    Acta Med Okayama; 2006 Oct; 60(5):295-8. PubMed ID: 17072376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suspected paclitaxel-induced pneumonitis.
    Shitara K; Ishii E; Kondo M; Sakata Y
    Gastric Cancer; 2006; 9(4):325-8. PubMed ID: 17235637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel-containing combination chemotherapy for metastatic breast cancer.
    Hortobagyi GN; Ibrahim N
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):53-7. PubMed ID: 8629039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.